Stocktoria
Foghorn Therapeutics Inc. FHTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-23
Foghorn Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M |
| R&D expense | $85.5M | $94.5M | $109.7M | $105.6M | $80.3M |
| Operating income | -$86.4M | -$102.7M | -$107.9M | -$117.1M | -$100.7M |
| Interest expense | — | — | — | — | $1.9M |
| Income tax | $0 | $0 | $4.2M | $0 | — |
| Net income | -$74.3M | -$86.6M | -$98.4M | -$108.9M | -$101.3M |
| EPS (diluted) | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 |
| Operating cash flow | -$86.1M | -$100.4M | -$118.1M | $193.6M | -$50.2M |
| Free cash flow | -$86.1M | -$101.3M | -$119.3M | $192.4M | -$53.6M |
| Cash & equivalents | $80.9M | $55.5M | $80.3M | $52.2M | $101.1M |
| Total assets | $198.1M | $284.0M | $285.9M | $404.9M | $519.8M |
| Total liabilities | $306.6M | $329.5M | $363.1M | $404.8M | $422.9M |
| Shareholders' equity | -$108.5M | -$45.5M | -$77.2M | $112,000 | $96.9M |
Source: SEC EDGAR filings · CIK 0001822462 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.